alarming patients about the safety of Humira (adalimumab) and Remicade (infliximab)
July 2006
A recent analysis is alarming patients about the safety of Humira (adalimumab) and Remicade (infliximab).
These TNF inhibitors are wonder drugs for many patients with rheumatoid arthritis, Crohn's, and other autoimmune diseases.
But there's concern about an increased risk of serious infections and malignancies. Tumor necrosis factor plays a role in fighting infections and killing tumor cells.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter membership benefits include:
- 12 issues every year — what you need to know and do, right now
- Quick, practical reference charts and tools
- Comprehensive CE library to meet license renewal and state requirements
- Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
- Plus much more!
Choose the right tier for your needs today.
Already a subscriber? Log in
Volume pricing available. Get a quote